Upgrade to SI Premium - Free Trial

Editas Medicine (EDIT)

2.71 -0.28 (9.36%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/5/26)

Latest Headlines

Form 4 Editas Medicine, Inc. For: Jun 03 Filed by: Parison Amy June 5, 2026 4:33 PM - SEC Filing Form 4 Editas Medicine, Inc. For: Jun 03 Filed by: O'Neill Gilmore Neil June 5, 2026 4:33 PM - SEC Filing Form 4 Editas Medicine, Inc. For: Jun 03 Filed by: Burkly Linda June 5, 2026 4:32 PM - SEC Filing Form SCHEDULE 13G Editas Medicine, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P. June 3, 2026 4:46 PM - SEC Filing Form SCHEDULE 13G Editas Medicine, Inc. Filed by: TCG Crossover GP III, LLC June 3, 2026 4:17 PM - SEC Filing Form SCHEDULE 13G Editas Medicine, Inc. Filed by: Commodore Capital LP June 2, 2026 5:32 PM - SEC Filing Form 144 Editas Medicine, Inc. Filed by: O'Neill Gilmore Neil May 29, 2026 4:40 PM - SEC Filing Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference May 28, 2026 4:01 PM - StreetInsider Increasing unusual option volume: CRSR NASA APPS EDIT AMPG MRLN AOSL EMN BEAM May 27, 2026 10:14 AM - StreetInsider Form 424B5 Editas Medicine, Inc. May 26, 2026 5:31 PM - SEC Filing Form 8-K Editas Medicine, Inc. For: May 26 May 26, 2026 4:43 PM - SEC Filing Editas Medicine prices $125 million public offering of stock and warrants May 26, 2026 9:05 AM - StreetInsider Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering May 26, 2026 9:05 AM - StreetInsider Form S-3MEF Editas Medicine, Inc. May 26, 2026 8:36 AM - SEC Filing Form 8-K Editas Medicine, Inc. For: May 26 May 26, 2026 8:07 AM - SEC Filing Form 424B5 Editas Medicine, Inc. May 26, 2026 6:27 AM - SEC Filing Editas Medicine announces public offering of stock and warrants May 26, 2026 6:15 AM - StreetInsider Editas Medicine Announces Proposed Public Offering May 26, 2026 6:15 AM - Globe NewsWire Form 8-K Editas Medicine, Inc. For: May 25 May 26, 2026 6:10 AM - SEC Filing Editas Medicine reports 90% cholesterol reductions in primate study May 26, 2026 6:01 AM - StreetInsider Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress May 26, 2026 6:01 AM - StreetInsider Form 8-K Editas Medicine, Inc. For: May 14 May 14, 2026 6:16 AM - SEC Filing Editas Medicine shares new data on EDIT-401 cholesterol treatment May 14, 2026 6:01 AM - StreetInsider Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting May 14, 2026 6:01 AM - Globe NewsWire Form 10-Q Editas Medicine, Inc. For: Mar 31 May 5, 2026 4:18 PM - SEC Filing Form 8-K Editas Medicine, Inc. For: May 05 May 5, 2026 7:03 AM - SEC Filing Editas Medicine Announces First Quarter 2026 Results and Business Updates May 5, 2026 7:00 AM - Globe NewsWire Form ARS Editas Medicine, Inc. For: Apr 28 April 28, 2026 4:39 PM - SEC Filing Form DEFA14A Editas Medicine, Inc. April 28, 2026 4:37 PM - SEC Filing Form DEF 14A Editas Medicine, Inc. For: Apr 28 April 28, 2026 4:35 PM - SEC Filing Editas Medicine to present EDIT-401 data at scientific conferences April 27, 2026 4:31 PM - StreetInsider Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences April 27, 2026 4:31 PM - Globe NewsWire Editas Medicine (EDIT) PT Raised to $15 at Evercore ISI April 10, 2026 3:15 PM - StreetInsider Form 8-K Editas Medicine, Inc. For: Apr 01 April 7, 2026 4:29 PM - SEC Filing Jones Trading Assumes Editas Medicine (EDIT) at Buy April 6, 2026 4:16 PM - StreetInsider Form 8-K Editas Medicine, Inc. For: Mar 26 March 27, 2026 7:02 AM - SEC Filing Editas Medicine wins CRISPR patent ruling from USPTO March 27, 2026 7:00 AM - StreetInsider Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference March 27, 2026 7:00 AM - StreetInsider Form SCHEDULE 13G/A Editas Medicine, Inc. Filed by: VANGUARD GROUP INC March 26, 2026 6:05 PM - SEC Filing Form 4 Editas Medicine, Inc. For: Mar 12 Filed by: O'Neill Gilmore Neil March 16, 2026 4:38 PM - SEC Filing Form 4 Editas Medicine, Inc. For: Mar 12 Filed by: Parison Amy March 16, 2026 4:36 PM - SEC Filing Form 4 Editas Medicine, Inc. For: Mar 12 Filed by: Burkly Linda March 16, 2026 4:35 PM - SEC Filing Jones Trading Upgrades Editas Medicine (EDIT) to Buy, 'Potentially Best-in-Class Preclinical Data' March 10, 2026 10:19 AM - StreetInsider Full Article List